Sarepta Therapeutics (SRPT) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Xencor (XNCR) has outperformed Sarepta Therapeutics (SRPT) over the past year, gaining 101.7% versus a loss of 24.3%. Over five years, XNCR leads with a -36.9% price change compared with -79.2% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.85 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRPT | XNCR |
|---|---|---|
| Share price | $17.50 | $24.26 |
| Market cap | $1.85B | $1.80B |
| 1-day change | +1.10% | -0.41% |
| YTD return | -18.68% | +58.46% |
| 1-year return | -24.31% | +101.66% |
| 5-year return | -79.21% | -36.94% |
| Forward P/E | 7.26 | — |
| EPS (TTM) | $-1.57 | $-2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.32 | $30.61 |
| 52-week low | $14.68 | $10.38 |
| Distance from 52-week high | -30.88% | -20.74% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +24.17% | +29.51% |
| Average volume | 2.99M | 1.30M |
| Shares outstanding | 105.63M | 74.35M |
| Employees | 835 | 260 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed SRPT by 126.0 percentage points over the past year.
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Healthcare · Biotechnology · 835 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Healthcare · Biotechnology · 260 employees
SRPT vs XNCR FAQ
Which is bigger, Sarepta Therapeutics or Xencor?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.85B compared with $1.80B for Xencor (XNCR).
Which stock has performed better over the past year, SRPT or XNCR?
XNCR returned +101.66% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Sarepta Therapeutics and Xencor in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.